Making it Possible

Envision a world where progressive myopia is a thing of the past.

With our transformative microdosing technology, we are developing a treatment for progressive myopia, a condition which is associated with several back of the eye diseases and may result in visual disability.

Making it Possible

Envision a world where progressive myopia is a thing of the past.

With our transformative microdosing technology, we are developing a treatment for progressive myopia, a condition which is associated with several back of the eye diseases and may result in visual disability.

Latest News

Eyenovia, Inc. Announces Adjournment of 2020
Annual Meeting of Stockholders

Recent News Releases
06/11/20   Eyenovia, Inc. Announces Adjournment of 2020 Annual Meeting of Stockholders to June 30, 2020  and Change to a Virtual Meeting Format   Read More
06/05/20  Eyenovia Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format   Read More
05/13/20  Eyenovia Reports First Quarter 2020 Financial Results   Read More

A Transformative Biopharmaceutical Company

Eyenovia is a clinical stage, ophthalmic biopharmaceutical company that is transforming therapies primarily for the treatment of progressive myopia, presbyopia, and improving diagnostic eye exams. We believe our breakthrough technology enables these first-in-class microdosed therapies that are designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing drugs.

See How We Make it Possible

Vision-Logo-120619v2

Vision

VISION, our phase III NDA enabling study for the temporary improvement in sight for adults with presbyopia
is scheduled to enroll and complete in 2020.

More information coming soon!

These results showed the efficacy and safety of the fixed combination microdose formulation
and the potential for offices to improve their patient flow. 

Close Menu